Checkpoint Therapeutics Inc - ESG Rating & Company Profile powered by AI
This SDG assessment for Checkpoint Therapeutics Inc represents the company's reporting of the UN Sustainable Development Goals. Complete Sustainability assessment of Checkpoint Therapeutics Inc are reached by registering for free. Alternative corporations in the rating peer group for Checkpoint Therapeutics Inc are shown below.
Checkpoint Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.3; made up of an environmental score of 4.0, social score of 4.0 and governance score of 8.0.
5.3
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 886 | Veracyte Inc | 5.4 | High |
| 886 | Xlife Sciences AG | 5.4 | High |
| 912 | Checkpoint Therapeutics Inc | 5.3 | High |
| 912 | Acer Therapeutics Inc | 5.3 | High |
| 912 | Alembic Pharmaceuticals Ltd | 5.3 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Checkpoint Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Checkpoint Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Checkpoint Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Checkpoint Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Checkpoint Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Checkpoint Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Checkpoint Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Checkpoint Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.